Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 179 citing articles:

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
Brigida Barberio, David J. Gracie, Christopher J. Black, et al.
Gut (2022) Vol. 72, Iss. 2, pp. 264-274
Open Access | Times Cited: 96
Crohn's disease
Michael Dolinger, Joana Torres, Séverine Vermeire
The Lancet (2024) Vol. 403, Iss. 10432, pp. 1177-1191
Closed Access | Times Cited: 94
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Bram Verstockt, Azucena Salas, Bruce E. Sands, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 91
Strategies for targeting cytokines in inflammatory bowel disease
Markus F. Neurath
Nature reviews. Immunology (2024) Vol. 24, Iss. 8, pp. 559-576
Closed Access | Times Cited: 74
Oxidative Stress, Inflammation, Gut Dysbiosis: What Can Polyphenols Do in Inflammatory Bowel Disease?
Lei Li, Peilan Peng, Ning Ding, et al.
Antioxidants (2023) Vol. 12, Iss. 4, pp. 967-967
Open Access | Times Cited: 54
Improving IBD outcomes in the era of many treatment options
Taku Kobayashi, Toshifumi Hibi∥
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 2, pp. 79-80
Open Access | Times Cited: 51
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing
Markus F. Neurath, Michael Vieth
Gut (2023) Vol. 72, Iss. 11, pp. 2164-2183
Closed Access | Times Cited: 48
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
Laurent Peyrin‐Biroulet, J. Casey Chapman, Jean‐Frédéric Colombel, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 3, pp. 213-223
Closed Access | Times Cited: 31
Navigating the complexities of drug development for inflammatory bowel disease
Sailish Honap, Vipul Jairath, Silvio Danese, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 7, pp. 546-562
Closed Access | Times Cited: 21
The emerging role of oxidative stress in inflammatory bowel disease
P. De Muro, Li Zhang, Shuxuan Li, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 18
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 11, pp. 1312-1334
Open Access | Times Cited: 14
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease
Shahida Din, Christian P. Selinger, Christopher J. Black, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 6, pp. 666-675
Open Access | Times Cited: 41
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson, Maria Barsky, Waseem Ahmed, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 2, pp. 317-328
Closed Access | Times Cited: 40
Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
Javier P. Gisbert, María José García, María Chaparro
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 6, pp. 972-994
Closed Access | Times Cited: 35
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
Jean‐Frédéric Colombel, Ryan C. Ungaro, Bruce E. Sands, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 7, pp. 1487-1496.e12
Open Access | Times Cited: 31
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
Christina Kapizioni, R Desoki, Danielle Lam, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 6, pp. 790-800
Open Access | Times Cited: 29
Targeting IL-23 for IBD: Rationale and Progress to Date
Sudheer K. Vuyyuru, Lisa M. Shackelton, Jurij Hanžel, et al.
Drugs (2023) Vol. 83, Iss. 10, pp. 873-891
Closed Access | Times Cited: 25
Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
Brian Bressler
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 22
Clinical guidelines. Crohn’s disease (К50), adults
Yu. A. Shelygin, В. Т. Ивашкин, С. И. Ачкасов, et al.
Koloproktologia (2023) Vol. 22, Iss. 3, pp. 10-49
Open Access | Times Cited: 22
A Review of Available Medical Therapies to Treat Moderate-to-Severe Inflammatory Bowel Disease
Sam S. Chang, Megan E. Murphy, Lisa Malter
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 1, pp. 55-80
Closed Access | Times Cited: 21
Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics
Yuting Liu, Ziqi Lin, Yuting Wang, et al.
Theranostics (2024) Vol. 14, Iss. 6, pp. 2490-2525
Open Access | Times Cited: 12
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Marc Ferrante, Geert R. D’Haens, Vipul Jairath, et al.
The Lancet (2024) Vol. 404, Iss. 10470, pp. 2423-2436
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top